Table 1 Baseline patient and disease characteristics of the study population
From: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Melanoma patients N = 69 | Healthy Controls N = 20 | |||
|---|---|---|---|---|
N | % | N | % | |
Age | ||||
Median, years# | 63 | 66 | ||
Range | 21–87 | 26–75 | ||
Gender | ||||
Male | 42 | 60,9 | 13 | 65 |
Female | 27 | 39,1 | 7 | 35 |
BRAF mutation | ||||
No | 33 | 47,9 | NA | NA |
Yes | 25 | 36.2 | NA | NA |
Not available | 11 | 15,9 | ||
Line of treatment | ||||
1 | 55 | 79,7 | NA | NA |
2 and 3 | 14 | 20,3 | NA | NA |
Distant metastasis | ||||
M1a | 12 | 17,4 | NA | NA |
M1b | 15 | 21,7 | NA | NA |
M1c | 31 | 45 | NA | NA |
M1d | 11 | 15,9 | NA | NA |
LDH | ||||
Normal | 43 | 62,3 | NA | NA |
Upper limit of normal | 25 | 36,2 | NA | NA |
Not available | 1 | 1,5 | ||
Stage | ||||
IIIC | 2 | 2,9 | NA | NA |
IV | 67 | 97,1 | NA | NA |